GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
Rhea-AI Summary
GT Biopharma (NASDAQ: GTBP) announced that Michael Breen, Executive Chairman and CEO, will participate in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5, 2026 in Toronto.
Format includes a presentation, panel discussion and one-on-one investor meetings; the company will be available for 1x1 meetings throughout the day (8:00 AM–5:00 PM EDT).
Positive
- None.
Negative
- None.
News Market Reaction – GTBP
In the Feb 17 session, GTBP declined 1.42%, reflecting a mild negative market reaction. Argus tracked a peak move of +18.8% during that session. Argus tracked a trough of -14.3% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | IND clearance | Positive | +2.3% | FDA cleared IND for GTB-5550 enabling Phase 1 solid tumor trial. |
| Jan 15 | IND submission | Positive | +10.6% | Submitted IND for GTB-5550 with planned Phase 1 basket trial. |
| Nov 19 | Pipeline update | Positive | +3.7% | Outlined progress on GTB-3650, GTB-5550, and GTB-7550 programs. |
| Nov 14 | Earnings & update | Neutral | +26.1% | Reported Q3 2025 results with cash, expenses, and trial timelines. |
| Oct 23 | Trial safety update | Positive | +9.0% | Phase 1 GTB-3650 advanced after no safety issues in Cohort 3. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinical, regulatory, and financing milestones often coincided with positive next-day price reactions.
Over the last few months, GT Biopharma has focused on advancing its TriKE® NK cell engager pipeline and shoring up its capital structure. Key items included FDA IND clearance for GTB‑5550 with cash projected through Q4 2026, earlier GTB‑5550 IND submission plans, and multiple GTB‑3650 Phase 1 updates showing no major safety issues. Q3 2025 results highlighted low cash and going‑concern language. Against that backdrop, this conference appearance mainly reinforces visibility rather than adding new clinical or financial data.
Key Terms
immuno-oncology medical
natural killer (NK) cell medical
investor meetings financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5th, 2026, in Toronto, Ontario.
Centurion One Capital 9th Annual Toronto Growth Conference
Format: Presentation, panel discussion and 1x1 investor meetings
Presentation Date: Thursday, March 5th, 2026
Time: 8:00 AM EDT – 5:00 PM EDT
The Company will be available for one-on-one meetings at the conference. If interested, please contact your Centurion One Capital representative.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
LinkedIn |Facebook |X |Instagram | YouTube
